Risk factors

Mannkind (MNKD) risk factors

Item 1A of every Mannkind Corp. 10-K on file, and what changed from one year to the next. Readings are automated and can be wrong; check the filing for the exact wording.

Open MNKD in Gloom →
Mannkind's chart, financials and news, free in your browser.Open MNKD in Gloom →
  • FY2025 10-K risk factors
    61 risks13 new6 dropped16 reworded

    Partner United Therapeutics may prioritize its new Tresmi drug over Tyvaso DPI, hurting revenues.

    Filed Feb 26, 2026
  • FY2024 10-K risk factors
    54 risks

    Commercializing therapeutic products and relying on the Danbury facility for Afrezza and Tyvaso DPI manufacturing dominate MannKind's risk profile.

    Filed Feb 26, 2025